This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Apoaequorin
Apoaequorin is a calcium-binding protein originally derived from the bioluminescent jellyfish Aequorea victoria. Marketed primarily under the brand name Prevagen, it is promoted for memory support, though its evidence base is limited and largely brand-sponsored.
Benefits
What is Apoaequorin?
Apoaequorin is a 22-kDa protein that was first isolated from the jellyfish Aequorea victoria in the 1960s by researchers studying bioluminescence. In the jellyfish, apoaequorin combines with the cofactor coelenterazine and calcium ions to produce the bioluminescent protein aequorin, which emits blue light upon calcium binding. The protein is now produced via recombinant DNA technology in E. coli bacteria.
The nootropic rationale for apoaequorin centres on its calcium-binding properties. As neurons age, their ability to regulate intracellular calcium declines, and excess calcium can trigger excitotoxicity, oxidative stress, and cell death. The theory is that supplemental apoaequorin could help buffer excess intracellular calcium, protecting neurons from calcium-mediated damage.
However, the scientific community remains sceptical. The primary concern is bioavailability - as a protein, apoaequorin is likely digested in the stomach and intestines before reaching the brain. There is no published evidence demonstrating that oral apoaequorin survives digestion, crosses the blood-brain barrier, or reaches neurons in a functional form. The FTC challenged the manufacturer's advertising claims in court, and independent peer-reviewed research is limited.
- Calcium binding (theoretical): Apoaequorin has high affinity for calcium ions and could theoretically buffer excess intracellular calcium in neurons, preventing excitotoxicity - though whether oral supplementation achieves this is unproven.
- Neuroprotection (in vitro): Cell culture studies have shown that apoaequorin can protect neurons from calcium-induced cell death, but these results use direct application to cells, not oral delivery.
- Bioavailability concern: As a protein, apoaequorin is expected to be broken down by digestive enzymes (pepsin, trypsin) before absorption. No studies have demonstrated intact apoaequorin reaching the brain after oral ingestion.
- Brand-sponsored research: The primary clinical trial (Madison Memory Study) was funded by the manufacturer and showed modest improvements in some memory tasks. Independent replication is lacking.
- Marketed dose: 10 mg per day (as in Prevagen Regular Strength)
- Extra Strength: 20 mg per day (Prevagen Extra Strength)
- Professional: 40 mg per day (Prevagen Professional)
- Timing: Manufacturer recommends taking once daily, in the morning
- Duration: The manufacturer suggests 90 days for full effects
Apoaequorin is available almost exclusively as the branded product Prevagen. Independent or generic versions are uncommon.
- Side effects: Generally well tolerated in reported studies. Occasional reports of headache, dizziness, and nausea.
- FTC action: In 2017, the US Federal Trade Commission and New York Attorney General sued the manufacturer for false advertising, alleging the clinical evidence did not support the memory claims. The case had mixed outcomes.
- Protein allergy: As a protein derived from jellyfish (produced recombinantly), allergic reactions are theoretically possible though rarely reported.
- Drug interactions: No significant drug interactions reported.
- Pregnancy: Insufficient data. Consult a healthcare provider.
Apoaequorin appears safe but its efficacy for cognitive enhancement remains poorly supported by independent research. Consumers should weigh the limited evidence against the relatively high cost.
Natural Sources & Forms
- Prevagen: The primary (and essentially only) commercial source, manufactured by Quincy Bioscience
- Recombinant production: Modern apoaequorin is produced in bacteria using recombinant DNA technology, not extracted from jellyfish
- No natural dietary sources: Apoaequorin is not found in any common foods
Frequently Asked Questions
Apoaequorin is a calcium-binding protein originally derived from the bioluminescent jellyfish Aequorea victoria. Marketed primarily under the brand name Prevagen, it is promoted for memory support, though its evidence base is limited and largely brand-sponsored.
The key benefits of Apoaequorin include: Anxiety & Calm, Cognitive Enhancement, Focus, Longevity, Memory, Mood.
Calcium binding (theoretical): Apoaequorin has high affinity for calcium ions and could theoretically buffer excess intracellular calcium in neurons, preventing excitotoxicity - though whether oral supplementation achieves this is unproven. Neuroprotection (in vitro): Cell culture studies have shown that apoaequorin can protect neurons from calcium-induced cell death, but these results use direct application to cells, not oral delivery. Bioavailability concern: As a protein, apoaequorin is expected to be broken down by digestive enzymes (pepsin, trypsin) before absorption. No studies have demonstrated intact apoaequorin reaching the brain after oral ingestion. Brand-sponsored research: The primary clinical trial (Madison Memory Study) was funded by the manufacturer and showed modest improvements in some memory tasks. Independent replication is lacking.
Marketed dose: 10 mg per day (as in Prevagen Regular Strength) Extra Strength: 20 mg per day (Prevagen Extra Strength) Professional: 40 mg per day (Prevagen Professional) Timing: Manufacturer recommends taking once daily, in the morning Duration: The manufacturer suggests 90 days for full effects Apoaequorin is available almost exclusively as the branded product Prevagen. Independent or generic versions are uncommon.
Side effects: Generally well tolerated in reported studies. Occasional reports of headache, dizziness, and nausea. FTC action: In 2017, the US Federal Trade Commission and New York Attorney General sued the manufacturer for false advertising, alleging the clinical evidence did not support the memory claims. The case had mixed outcomes. Protein allergy: As a protein derived from jellyfish (produced recombinantly), allergic reactions are theoretically possible though rarely reported. Drug interactions: No significant drug interactions reported. Pregnancy: Insufficient data. Consult a healthcare provider. Apoaequorin appears safe but its efficacy for cognitive enhancement remains poorly supported by independent research. Consumers should weigh the limited evidence against the relatively high cost.
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!